Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment.
Jonathan Ian SilverbergAndreas WollenbergLinda F Stein GoldJames Q Del RossoGil YosipovitchPeter A LioY José Manuel CarrascosaGaia GalloYuxin DingZhenhui XuMarta CasillasEvangeline J PierceHelena AgellPamela GuglielminiPublished in: Dermatology and therapy (2024)
NCT04146363 (ADvocate1) and NCT04178967 (ADvocate2).